BREAKING: Inflation Data Cements Rate Cut Expectations President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on companies who don't have a manufacturing presence in the U.S. In a post on social media platform Truth Social, Trump said the administration will impose a 100% tariff starting Oct. 1 "on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America." The post adds to the fast- ...

Group 1 - Amgen Inc. is recognized as one of the best value stocks in Goldman Sachs' portfolio, with a Buy rating maintained by Piper Sandler analyst David Amsellem and a price target of $342 [1] - The upcoming FORTITUDE-102 study results, which combine bemarituzumab with chemotherapy and Opdivo, are crucial for Amgen's market potential, as highlighted by William Blair analyst Matt Phipps [2] - Amgen's pipeline strength is exemplified by the recommendation for approval of Tezspire (tezepelumab) in the EU, developed in collaboration with AstraZeneca for treating chronic rhinosinusitis with nasal polyps, affecting approximately 320 million people globally [3] Group 2 - In the collaboration agreement for Tezspire, AstraZeneca leads development while Amgen is responsible for manufacturing, with costs and profits shared equally after AstraZeneca pays a mid-single-digit inventor royalty to Amgen [4] - Amgen focuses on discovering, developing, and manufacturing innovative therapies in oncology, cardiovascular disease, inflammation, and rare diseases [4]

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly ...

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Cheap Quarterly Dividend Stocks to Buy Right Now. Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks? Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, offers investors a strong and diverse portfolio. It has more than two dozen brands, including several blockbuster drugs that each bring in over $1 billion in annual sales. Amgen Inc. (NASDAQ:AMGN)’s medicines span multiple therapeutic areas. These include Repatha, ...

Core Insights - Amgen Inc. (NASDAQ: AMGN) has experienced lackluster performance over the past two years, with a total return of only 13% since coverage was initiated in August 2023 [2]. Company Performance - The stock of Amgen has shown minimal growth, indicating potential challenges in its market performance [2]. Investment Focus - The Growth Stock Forum emphasizes identifying attractive risk/reward situations, particularly in the biotech sector, and closely tracks portfolio and watchlist stocks [1].

Core Insights - Amgen (NASDAQ: AMGN) has experienced lackluster performance over the past two years, with a total return of only 13% since coverage was initiated in August 2023 [2]. Company Performance - The stock of Amgen has shown minimal growth, indicating potential challenges in its market performance [2]. Investment Focus - The Growth Stock Forum emphasizes identifying attractive risk/reward situations, particularly in the biotech sector, and closely tracks portfolio and watchlist stocks [1].

花旗将安进的目标价从310美元上调至315美元，维持"持有"评级。(格隆汇) ...

Group 1 - President Xi Jinping announced China's new round of Nationally Determined Contributions at the UN Climate Change Summit, aiming for a 7%-10% reduction in greenhouse gas emissions by 2035, with non-fossil energy consumption exceeding 30% of total energy consumption [3] - The total installed capacity of wind and solar power is targeted to reach over 360 million kilowatts, six times that of 2020, and forest stock is expected to exceed 24 billion cubic meters [3] - The national carbon emissions trading market will cover major high-emission industries, and a climate-adaptive society is to be fundamentally established [3] Group 2 - Premier Li Qiang emphasized China's commitment to maintaining an open trade and investment market during a meeting with the President of the European Commission, urging fair competition and adherence to WTO rules [5] - The Chinese government will not seek new special and differential treatment in current and future WTO negotiations, reinforcing its role as a responsible developing country [5] - The People's Bank of China announced a 600 billion yuan MLF operation on September 25, marking a net injection of 300 billion yuan for the month, continuing a trend of high liquidity [5][6] Group 3 - Alibaba announced a collaboration with NVIDIA on Physical AI, with plans to invest 380 billion yuan in AI infrastructure and the launch of seven large model products, including Qwen3-Max, the largest and most capable model to date [4] - The Chinese Ministry of Commerce introduced 14 measures to promote digital consumption, including trials for smart connected vehicles and drone delivery services [6] Group 4 - The A-share market saw significant gains, with the Shanghai Composite Index rising 0.83% to 3853.64 points, and the ChiNext Index increasing by 2.28% [8] - The Hong Kong Hang Seng Index rose 1.37%, with notable gains in tech stocks like Alibaba and SMIC, while medical stocks faced declines [8] - Chery Automobile announced its H-share final offering price at 30.75 HKD per share, set to officially list on September 25 [8] Group 5 - The State Administration for Market Regulation is seeking public opinion on new standards for food delivery platforms, addressing issues like competition and delivery personnel rights [11] - The National Press and Publication Administration approved 145 domestic games and 11 imported games in September, indicating a positive trend in the gaming industry [12] Group 6 - The global crude steel production in August was 145.3 million tons, a year-on-year increase of 0.3%, while the cumulative production from January to August saw a decline of 1.7% [23] - The UK government faced challenges in issuing new bonds, with the latest five-year bond auction seeing the lowest oversubscription rate in nearly two years [20]

Group 1 - The article discusses Amgen Inc. and highlights impressive data from Imdelltra and Q1 results [1] - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The mission of Allka Research is to provide substantial returns and strategic insights, aiming to simplify investment strategies for both seasoned and novice investors [1] Group 2 - Allka Research seeks to empower individuals financially by sharing knowledge and analyses through Seeking Alpha [1] - The organization aims to inspire confidence in investors, fostering a community that can navigate the financial markets intelligently [1]

Core Insights - The article discusses Amgen Inc. and highlights the impressive data from Imdelltra and Q1 results, indicating a positive outlook for the company [1]. Group 1: Company Overview - Amgen Inc. is positioned as a significant player in the pharmaceutical industry, with a focus on delivering substantial returns and strategic insights [1]. - The company is part of a broader investment landscape that includes ETFs, commodities, and technology, showcasing its diversified approach [1]. Group 2: Investment Strategy - Allka Research emphasizes a conservative investment strategy, aiming to uncover undervalued assets and simplify investment approaches for both seasoned and novice investors [1]. - The mission of Allka Research is to provide thought-provoking analyses and informed perspectives, fostering a community of informed investors [1].